# PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

> **NCT03817320** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 24 (actual)

## Conditions studied

- ALL, Childhood
- Lymphoblastic Lymphoma, Childhood
- Lymphoblastic Leukemia, Acute, Childhood

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Asparaginase
- **DRUG:** Doxorubicin
- **DRUG:** Methotrexate (IT)
- **DRUG:** Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT03817320
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-12
- **Primary completion:** 2023-12-03
- **Final completion:** 2025-06-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817320, "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03817320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*